Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)

Conditions:   Type 2 Diabetes;   Proteinuria;   Stress;   Nephropathy
Intervention:  
Sponsors:   University of Manitoba;   Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified June 2016

Type 2 Diabetes and Alteration of Immune System of Intestinal Mucosa : Proof of Concept

Condition:   Type 2 Diabetes
Intervention:   Other: Biopsy
Sponsor:   University Hospital, Toulouse
Not yet recruiting - verified June 2016

Postprandial Metabolism After Bariatric Surgery in Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Obese
Interventions:   Procedure: biliopancreatic diversion with duodenal switch;   Procedure: sleeve gastrectomy;   Other: liquid meal;   Radiation: PET/scan;   Other: [7,7,8,8-2H]-palmitate;   Device: indirect calorimetry
Sponsors:   Université de Sherbrooke;   Laval University
Recruiting - verified March 2016

The DDI Study of SP2086 and Valsartan

Condition:   Type 2 Diabetes
Interventions:   Drug: SP2086;   Drug: Valsartan
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Recruiting - verified January 2016

The DDI Study of SP2086 and Simvastatin

Condition:   Type 2 Diabetes
Interventions:   Drug: SP2086;   Drug: Simvastatin
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Recruiting - verified March 2016

Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria

Condition:   Hypertension With Type 2 Diabetes and Albuminuria.
Intervention:   Drug: CS-3150
Sponsor:   Daiichi Sankyo Co., Ltd.
Not yet recruiting - verified June 2016

Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Bexagliflozin
Sponsor:   Theracos
Recruiting - verified June 2016

The Drug-drug Interaction of SP2086 and Metformin

Condition:   Type 2 Diabetes
Interventions:   Drug: SP2086;   Drug: Metformin
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Completed - verified December 2015

Mineralocorticoid Receptor Antagonists in Type 2 Diabetes

Condition:   Diabetes Type 2
Interventions:   Drug: Eplerenone;   Drug: Placebo
Sponsor:   Herlev Hospital
Recruiting - verified June 2016

Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Exenatide-LAR plus Dapagliflozin placebo;   Drug: Exenatide-LAR plus Dapagliflozin;   Drug: Insulin Titration;   Behavioral: Behavioral Therapy
Sponsor:   Weill Medical College of Cornell University
Recruiting - verified June 2016

A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes

Conditions:   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Drug: LY900018
Sponsors:   Eli Lilly and Company;   Locemia Solutions ULC
Completed - verified June 2016

Sucralose in Subjects With Diabetes Mellitus Insulin Requesting

Condition:   Diabetes Mellitus, Type 2
Interventions:   Other: Sucralose;   Other: Placebo
Sponsor:   Universidad de Valparaiso
Completed - verified June 2016

Pharmacological Activation of Brown Adipose Tissue Metabolism

Condition:   Type 2 Diabetes
Interventions:   Drug: Mirbetriq (Mirabegron);   Other: cold exposure;   Radiation: injection of 18FDG;   Radiation: injection of 11C-acetate;   Radiation: [3-3H]-glucose;   Other: [U-13C]-palmitate;   Other: 2H-Glycerol
Sponsor:   Université de Sherbrooke
Not yet recruiting - verified June 2016

Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus

Condition:   Type II Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Not yet recruiting - verified June 2016

The Effects of a Six-week Exercise Programme Undertaken by Women With Rheumatoid Arthritis

Conditions:   Rheumatoid Arthritis;   Physical Activity
Intervention:   Behavioral: Exercise Intervention
Sponsors:   Siobhan Graham;   University of Bath
Recruiting - verified June 2016

FreeStyle Libre- Effect on QOL in Type 2 Diabetes Patients

Condition:   Type 2 Diabetes
Interventions:   Device: FreeStyle Libre;   Device: personal glucometer
Sponsor:   Wolfson Medical Center
Recruiting - verified June 2016

Technology-augmented Self-monitoring Model Among Patients With Type 2 Diabetes and Hypertension

Conditions:   Type 2 Diabetes Mellitus;   Hypertension
Intervention:   Device: Technology-based self-management model
Sponsor:   The University of Hong Kong
Recruiting - verified June 2016

Evaluate the Value of Telehomecare for Diabetes

Condition:   Type 2 Diabetes
Intervention:   Device: BlueStar app
Sponsors:   Women's College Hospital;   North York General Hospital;   William Osler Health System;   St. Joseph's Care Group;   Ontario Telemedicine Network (OTN);   St. Michael's Hospital, Toronto
Recruiting - verified June 2016

The Correlation Between the Retrobulbar Hemodynamics and Intrarenal Hemodynamics in T2DM Patients During the Early Period

Condition:   Diabetes Mellitus, Type 2
Intervention:   Device: Color doppler imaging
Sponsor:   Fourth People's Hospital of Shenyang
Completed - verified June 2016

Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Beraprost;   Drug: Aspirin
Sponsor:   Astellas Pharma Inc
Terminated - verified May 2016

A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes

Conditions:   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Drug: LY900018
Sponsors:   Eli Lilly and Company;   Locemia Solutions ULC
Terminated - verified June 2016

Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin

Conditions:   Type 2 Diabetes;   Hypertension
Interventions:   Biological: Blood sampling;   Procedure: Blood Pressure Measurement;   Device: electrocardiogram;   Procedure: orthostatic test;   Drug: Administration of Aprepitant;   Drug: Administration of placebo
Sponsor:   University Hospital, Rouen
Not yet recruiting - verified June 2016

An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Exenatide;   Drug: Albiglutide
Sponsors:   GlaxoSmithKline;   Wake Forrest Baptist Health
Not yet recruiting - verified June 2016

A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified June 2016

Chronic Cold Acclimation Stimulates the Browning of Subcutaneous White Adipose in Patients With Type 2 Diabetes Mellitus

Conditions:   Type 2 Diabetes;   Cold Acclimation
Intervention:   Other: Chronic cold acclimation
Sponsor:   Xiang Guang-da
Recruiting - verified June 2016

Reaching Better Health Study: A Website to Improve Type 2 Diabetes Self-Management

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Health & Wellness Website;   Other: Control Arm
Sponsors:   Children's Hospital of Philadelphia;   Merck Sharp & Dohme Corp.;   University of Pennsylvania
Enrolling by invitation - verified June 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Recruiting - verified June 2016

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine U100 (HOE901);   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified June 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Lixisenatide (AVE0010);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Recruiting - verified June 2016

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Device: Auto-injector
Sponsor:   GlaxoSmithKline
Not yet recruiting - verified June 2016

Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D)

Condition:   Impaired Glucose Tolerance
Interventions:   Drug: Nicotinic acid;   Other: [7,7,8,8-2H]-palmitate;   Other: [U-13C]-palmitate;   Procedure: Biopsy;   Other: liquid meal
Sponsor:   Université de Sherbrooke
Not yet recruiting - verified June 2016

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo to stiagliptin;   Drug: Metformin;   Drug: Metformin XR;   Drug: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified June 2016

Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010;   Drug: Insulin glargine HOE901;   Drug: Placebo
Sponsor:   Sanofi
Completed - verified June 2016

A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ipragliflozin L-proline;   Drug: Metformin;   Drug: Placebo
Sponsor:   Astellas Pharma Europe B.V.
Recruiting - verified June 2016

A Study of the GI Sleeve for the Treatment of Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Device: EndoBarrier Gastrointestinal Liner;   Other: Sham: endoscopy and standard of care
Sponsors:   GI Dynamics;   Hospital Dipreca
Completed - verified March 2016

Effect of Roux-en-Y Gastric Bypass or Gastric Sleeve Surgery on Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Obesity
Interventions:   Procedure: Roux-en-Y Gastric Bypass;   Procedure: Gastric Sleeve
Sponsors:   University of Aarhus;   University of Copenhagen
Not yet recruiting - verified February 2016

Community Health Workers and Diabetes Education

Condition:   Diabetes
Interventions:   Behavioral: diabetes education;   Behavioral: education in other areas
Sponsors:   Hospital de Clinicas de Porto Alegre;   Associação Fundo de Incentivo à Pesquisa
Completed - verified June 2016

Defining the Physiological Mechanisms of Risk Genes for Hyperglycaemia, Insulin Resistance and Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Other: 4 Hour Frequently Sampled Oral Glucose Tolerance Test;   Other: Isoglycaemic Clamp
Sponsors:   University of Oxford;   University of Exeter;   Medical Research Council
Recruiting - verified June 2016

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

Conditions:   Heart Diseases;   Diabetes Mellitus, Type 2
Interventions:   Drug: RAS-antagonist and beta-blocker up-to maximal dosages;   Other: RAS-antagonist and beta-blocker none or at stable dose
Sponsor:   Martin Huelsmann
Recruiting - verified June 2016

A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: TTP273;   Drug: Placebo
Sponsor:   vTv Therapeutics
Recruiting - verified June 2016

Smart and Secure Children Program for Preschool Obesity

Conditions:   Obesity;   Type 2 Diabetes
Interventions:   Behavioral: SSC Program;   Behavioral: Written Handouts
Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   University of Houston
Recruiting - verified June 2016

A Performance Evaluation of the Enlite 3 Sensor

Condition:   Type 1 Diabetes
Intervention:   Device: Enlite 3 Sensor
Sponsor:   Medtronic Diabetes
Withdrawn - verified June 2016

The Drug-drug Interaction of SP2086 and Simvastatin

Condition:   Type 2 Diabetes
Interventions:   Drug: SP2086;   Drug: Simvastatin
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Completed - verified June 2016

The Drug -Drug Interaction of SP2086 and Glyburide

Condition:   Type 2 Diabetes
Interventions:   Drug: SP2086;   Drug: Glyburide
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Completed - verified June 2016

The Metabolite Identification and Material Balance Study of SP2086

Condition:   Type 2 Diabetes
Intervention:   Drug: SP2086
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Completed - verified November 2015

The Drug-drug Interaction of SP2086 and Valsartan

Condition:   Type 2 Diabetes
Interventions:   Drug: SP2086;   Drug: Valsartan
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Completed - verified June 2016

Loop Duodenal Switch Surgery in Morbidly Obese Patients

Conditions:   Obesity;   Type-2 Diabetes Mellitus
Intervention:   Procedure: Loop duodenal switch
Sponsor:   Medical College of Wisconsin
Recruiting - verified June 2016

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 15 mg;   Drug: Placebo matching ertugliflozin;   Drug: Metformin;   Drug: Glimepiride
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified June 2016

Impact of Rheumatoid Arthritis on the Course of Type 2 Diabetes During a Longitudinal Follow-up of 5 Years

Condition:   Type 2 Diabetes
Intervention:  
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Recherche Clinique Paris Descartes Necker Cochin Sainte Anne
Recruiting - verified June 2016

A Pragmatic Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Standard of Care
Sponsors:   AstraZeneca;   Quintiles, Inc.;   Clinical Practice Research Datalink
Not yet recruiting - verified June 2016

Optimization of Interval-training in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: CON;   Behavioral: IW-60;   Behavioral: IW-45
Sponsor:   Rigshospitalet, Denmark
Active, not recruiting - verified June 2016

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Insulin Resistance
Interventions:   Drug: Metformin;   Drug: saxagliptin;   Drug: AZD9668;   Drug: placebo
Sponsors:   Nick Giannoukakis, PhD;   National Institutes of Health (NIH);   University of Pittsburgh;   University of South Florida;   AstraZeneca
Recruiting - verified June 2016

ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   The University of Texas Health Science Center at San Antonio;   AstraZeneca
Recruiting - verified June 2016

Interval-training and Appetite Regulation in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: CON;   Behavioral: CW;   Behavioral: IW
Sponsor:   Rigshospitalet, Denmark
Active, not recruiting - verified June 2016

Effect of Enhanced Counseling Using Complementary Feeding Recommendation Based on Linear Programming on Nutritional Status,Omega-3 Fatty Acids, Malondialdehyde, and Alpha-Tocopherol in Overweight Children in East Jakarta

Conditions:   Complementary Feeding Recommendation;   Linear Programming,;   Nutritional Status;   Omega-3 Fatty Acids;   Malondialdehyde;   Alpha-Tocopherol;   Overweight
Intervention:   Behavioral: Enhanced Counseling using CFR based on Linear Programming
Sponsors:   Indonesia University;   Danone Institute International
Completed - verified June 2016

Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore

Condition:   Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified June 2016

An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Human regular U-500 insulin (CSII);   Drug: Human regular U-500 insulin (MDI)
Sponsors:   Eli Lilly and Company;   Insulet Corporation
Recruiting - verified June 2016

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: PF-06291874;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified June 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified June 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified June 2016

Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer.

Conditions:   Foot Ulcer, Diabetic;   Epidermal Growth Factor
Interventions:   Drug: recombinant human Epidermal Growth Factor (rhEGF);   Other: Placebo
Sponsor:   The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Not yet recruiting - verified June 2016

Microarchitecture, Bone Strength and Fracture Risk in Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Bone Fractures
Intervention:  
Sponsors:   University Hospital, Basel, Switzerland;   University of Schleswig-Holstein
Recruiting - verified June 2016

Tofogliflozin GLP-1 Analogue Combination Trial

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Tofogliflozin;   Drug: GLP-1 analogue
Sponsors:   Kowa Company, Ltd.;   Sanofi
Active, not recruiting - verified June 2016

Prospective Evaluation of HIV Patients Using Non-invasive Methods for Estimation of Liver Fibrosis and Steatosis

Conditions:   Human Immunodeficiency Virus;   Acquired Immune Deficiency Syndrome Virus;   Liver Diseases;   Liver Cirrhosis;   Fibrosis
Intervention:  
Sponsor:   Oswaldo Cruz Foundation
Recruiting - verified June 2016

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Failure

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SYR-472 25 mg;   Drug: Placebo + SYR-472 25 mg
Sponsor:   Takeda
Recruiting - verified June 2016

Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes

Condition:   Maturity-Onset Diabetes of the Young
Intervention:   Other: insulin therapy
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified June 2016

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: MK-8521;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified June 2016

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2016

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Linagliptin;   Drug: Empagliflozin placebo + linagliptin placebo;   Drug: Empagliflozin + linagliptin low dose;   Drug: Linagliptin lacebo;   Drug: Empagliflozin + linagliptin high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified June 2016

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified June 2016

The Role of Arachidonic Acid Metabolites, From Patients With Metabolic Syndrome

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   University of Malaya
Recruiting - verified June 2016

Targeting Physical Activity to Improve Cardiovascular Health in Type 2 Diabetes

Conditions:   Motor Activity;   Health Behavior;   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Physical Activity;   Behavioral: Questionnaires
Sponsors:   University of Colorado, Denver;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2016

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Condition:   Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Glimepiride;   Other: Placebo
Sponsor:   AstraZeneca
Recruiting - verified June 2016

An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Low Metformin;   Drug: Mid Metformin;   Drug: High Metformin;   Drug: Metformin
Sponsor:   NuSirt Biopharma
Completed - verified June 2016

Evaluation of Duodenal Mucosal Resurfacing in Subjects With Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Diabetes Mellitus
Intervention:   Device: DMR Procedure (Fractyl)
Sponsor:   Fractyl Laboratories, Inc.
Recruiting - verified June 2016

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified June 2016

Role of Cardiometabolic Risk Factors in Childhood Bone Development

Conditions:   Obesity;   Cardiovascular Disease;   Type 2 Diabetes;   Osteoporosis
Intervention:   Other: Observational Study
Sponsor:   Georgia Regents University
Recruiting - verified June 2016

An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System

Condition:   Type 2 Diabetes
Intervention:   Device: EndoBarrier
Sponsor:   GI Dynamics
Withdrawn - verified November 2014

Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects

Condition:   Type 2 Diabetes
Intervention:   Drug: CRCHUM-MT cocktail
Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   Canadian Institutes of Health Research (CIHR)
Recruiting - verified June 2016

A Phase 2 Dose-finding Study of TAK-272 in Patients With Type 2 Diabetes Mellitus and Microalbuminuria

Condition:   Type 2 Diabetes Mellitus and Microalbuminuria
Interventions:   Drug: TAK-272 tablets;   Drug: Placebo tablets;   Drug: Candesartan cilexetil tablets
Sponsor:   Takeda
Recruiting - verified June 2016

Adult Accuracy Study of the Enlite 3 Glucose Sensor

Conditions:   Type 1 Diabetes;   Type 2 Diabetes
Interventions:   Device: Enlite 3;   Device: Guardian Mobile App;   Device: 640G Insulin Pump
Sponsor:   Medtronic Diabetes
Completed - verified June 2016

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Drug: Insulin Glargine and Insulin Lispro
Sponsors:   GlaxoSmithKline;   PPD
Recruiting - verified June 2016

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: Exenatide;   Drug: Exenatide matching placebo
Sponsor:   AstraZeneca
Active, not recruiting - verified June 2016

Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents

Conditions:   NAFLD;   TYPE 2 DIABETES;   METABOLIC SYNDROME
Interventions:   Dietary Supplement: Resveratrol;   Dietary Supplement: Placebo
Sponsors:   University of Manitoba;   DSM Nutritional Products, Inc.
Recruiting - verified June 2016

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2016

Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: Chiglitazar;   Drug: Sitagliptin
Sponsor:   Chipscreen Biosciences, Ltd.
Recruiting - verified June 2016

Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Low Metformin;   Drug: Metformin;   Drug: Mid Metformin;   Drug: High Metformin
Sponsor:   NuSirt Biopharma
Completed - verified June 2016

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified June 2016

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin (5 mg);   Drug: Ertugliflozin (15 mg);   Drug: Placebo;   Drug: Metformin;   Drug: Sitagliptin;   Drug: Glimepiride;   Biological: Insulin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Completed - verified June 2016

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified June 2016

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

Conditions:   Diabetes Mellitus, Type 2;   Diabetes
Interventions:   Drug: Metformin;   Drug: Detemir;   Drug: Liraglutide;   Drug: Insulin Aspart
Sponsor:   University of Texas Southwestern Medical Center
Recruiting - verified June 2016

Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)

Conditions:   Obesity;   Insulin Resistance;   Insulin Sensitivity;   Prediabetes;   Dyslipidemia;   Diabetes
Interventions:   Dietary Supplement: Placebo-Control;   Dietary Supplement: Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d);   Dietary Supplement: High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
Sponsors:   Georgia Regents University;   University of Alabama at Birmingham;   Yale University;   Tufts University;   NattoPharma, ASA
Recruiting - verified June 2016

Southeastern Diabetes Initiative Clinical Intervention

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Extension of Care
Sponsors:   Duke University;   Centers for Medicare and Medicaid Services;   Bristol-Myers Squibb
Completed - verified April 2015

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Cardiovascular Disease
Interventions:   Drug: Sitagliptin;   Drug: Glimepiride;   Drug: Placebo;   Drug: Placebo
Sponsors:   University of Colorado, Denver;   Merck Sharp & Dohme Corp.
Recruiting - verified June 2016

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2016

Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease

Conditions:   Coronary Heart Disease, Susceptibility to, 5;   Prediabetic State
Interventions:   Behavioral: Health coaching;   Genetic: Genetic risk counseling;   Behavioral: Standard risk assessment
Sponsors:   Duke University;   David Grant U.S. Air Force Medical Center
Active, not recruiting - verified June 2016

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

Plasma Triglyceride Extraction by The Muscle

Conditions:   Obesity;   Insulin Resistance
Interventions:   Drug: Insulin;   Drug: NG-monomethyl-L-arginine
Sponsors:   Mayo Clinic;   American Diabetes Association
Recruiting - verified June 2016

EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes

Condition:   Type 1 Diabetes
Interventions:   Drug: Metformin;   Drug: Placebo
Sponsors:   University of Colorado, Denver;   American Diabetes Association;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2016

Closed-loop Insulin Delivery in the General Ward

Condition:   Diabetes Mellitus
Interventions:   Device: Fully Automated Closed-Loop Insulin Delivery;   Device: Conventional insulin therapy
Sponsors:   University of Cambridge;   Cambridge University Hospitals NHS Foundation Trust;   European Foundation for the Study of Diabetes
Completed - verified June 2016

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   High Risk for Cardiovascular Event
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Placebo tablet
Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   The TIMI Study Group;   Hadassah Medical Organization
Active, not recruiting - verified June 2016

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta tablet
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified June 2016

Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: OAD;   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified June 2016

Resistance Training and Testosterone After Spinal Cord Injury

Condition:   Spinal Cord Injury
Interventions:   Procedure: Resistance Training and Testosterone Patches;   Drug: Testosterone Patches
Sponsors:   VA Office of Research and Development;   Virginia Commonwealth University
Active, not recruiting - verified June 2016

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified June 2016

A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo;   Drug: Gliclazide;   Drug: Glimepiride;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified June 2016

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Condition:   Children and Adolescent With Type 2 Diabetes
Interventions:   Drug: Exenatide Once Weekly;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified June 2016

Adding Liraglutide to High Dose Insulin: Breaking the Cycle

Conditions:   Type 2 Diabetes Mellitus;   Obesity
Interventions:   Drug: Liraglutide;   Drug: Saline
Sponsors:   Ildiko Lingvay;   Novo Nordisk A/S
Completed - verified June 2016

Prospective Follow-up of a Cohort of Pre-diabetics in the North of France (DiabeNord)

Condition:   Prediabetes
Intervention:   Other: Prediabetes screening and prospective follow-up over 5 years
Sponsor:   Nantes University Hospital
Active, not recruiting - verified June 2016

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: linagliptin;   Drug: glimepiride;   Drug: linagliptin placebo;   Drug: glimepride placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified June 2016

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

Conditions:   Gestational Diabetes Mellitus;   Type 2 Diabetes Mellitus;   Metabolic Syndrome;   Impaired Glucose Tolerance;   Disorder of Glucose Regulation
Interventions:   Drug: Metformin XR plus placebo;   Drug: Metformin XR plus liraglutide
Sponsors:   Woman's;   Novo Nordisk A/S
Recruiting - verified June 2016

30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.;   Drug: Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified June 2016

Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

Conditions:   Post Bariatricsurgery;   Hypoglycemia
Interventions:   Drug: Exendin-(9-39);   Drug: Atropine;   Drug: GLP-1 and GIP
Sponsor:   Cedars-Sinai Medical Center
Active, not recruiting - verified March 2016

N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy

Conditions:   Diabetic Nephropathies;   Proteinuria;   Oxidative Stress
Interventions:   Dietary Supplement: N-acetylcysteine;   Dietary Supplement: silibin;   Dietary Supplement: high-dose silibin;   Dietary Supplement: N-acetylcysteine placebo;   Dietary Supplement: silibin placebo
Sponsors:   The University of Texas Health Science Center at San Antonio;   National Center for Complementary and Integrative Health (NCCIH);   VA Office of Research and Development
Completed - verified June 2016

Pioglitazone on Pancreatic Steatosis and Bone Health

Conditions:   Obesity;   Type 2 Diabetes
Interventions:   Drug: pioglitazone;   Drug: placebo
Sponsors:   University of Texas Southwestern Medical Center;   National Institutes of Health (NIH)
Completed - verified November 2014

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: SYR-472;   Drug: SYR-472;   Drug: SYR-472;   Drug: SYR-472;   Drug: Placebo;   Drug: Sitagliptin
Sponsor:   Takeda
Completed - verified June 2016

Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: TAK-379;   Drug: TAK-379;   Drug: TAK-379;   Drug: Pioglitazone;   Drug: Placebo
Sponsor:   Takeda
Terminated - verified June 2016

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: Exenatide;   Drug: Exenatide
Sponsors:   AstraZeneca;   inVentiv Health Clinical
Recruiting - verified June 2016

Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: SYR-472;   Drug: SYR-472;   Drug: SYR-472;   Drug: SYR-472;   Drug: Placebo
Sponsor:   Takeda
Completed - verified June 2016

Preventing Microalbuminuria in Type 2 Diabetes

Condition:   Diabetes
Interventions:   Drug: Benazepril;   Drug: Valsartan;   Drug: Benazepril/Valsartan
Sponsors:   Mario Negri Institute for Pharmacological Research;   Agenzia Italiana del Farmaco
Active, not recruiting - verified June 2016

A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified June 2016

A Study of Aleglitazar in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Actos;   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified June 2016

The Metabolic Effects of Almond Consumption in Adults With Pre-Diabetes

Conditions:   Prediabetes;   Insulin Resistance;   Metabolic Syndrome
Interventions:   Behavioral: Almonds in a calorie controlled diet;   Behavioral: Nut free diet
Sponsors:   University of Medicine and Dentistry of New Jersey;   Almond Board of California
Completed - verified June 2016

Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes

Conditions:   Diabetes Mellitus;   Obesity
Intervention:   Procedure: Oral glucose tolerance test
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2015